Drug · CHEMBL595
PIOGLITAZONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PIOGLITAZONE. Drugs and targets, record CHEMBL595. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL595
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 103 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor gamma agonist | AGONIST | https://conductscience.org/library/genes/5468 |
Source ChEMBL
Diseases103
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| type 2 diabetes mellitus | Approval | EMA Human Drugs and TTD | 184 | 163 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| Insulin resistance | Phase 3 | ClinicalTrials.gov | 20 | 20 | https://conductscience.org/library/drugs?q=HP_0000855 |
| polycystic ovary syndrome | Phase 2 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0008487 |
| metabolic dysfunction-associated steatohepatitis | Phase 3 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| diabetes mellitus | Approval | ATC | 11 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005015 |
| chronic myeloid leukemia | Phase 2 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0011996 |
| non-alcoholic fatty liver | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=EFO_1001248 |
| obesity disorder | Phase 2 | ClinicalTrials.gov | 6 | 5 | https://conductscience.org/library/drugs?q=MONDO_0011122 |
| Impaired glucose tolerance | Unknown | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=HP_0040270 |
| chronic kidney disease | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
1 to 10 of 103Source Open Targets
See all 103 diseasesTrials449
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 12 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00091949 | Insulin Resistance Intervention After Stroke Trial | Phase 3 | 3,876 | 2016-10-28 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT01931566 | Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset | Phase 3 | 3,494 | 2019-08-14 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00736099 | Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM | Phase 3 | 2,122 | 2012-03-08 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00484198 | Study of Rivoglitazone in Type 2 Diabetes Mellitus | Phase 3 | 1,912 | 2021-07-27 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00722371 | MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) | Phase 3 | 1,615 | 2011-10-17 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00328627 | Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus. | Phase 3 | 1,554 | 2013-04-04 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00879970 | Thiazolidinedione Intervention With Vitamin D Evaluation | Phase 4 | 1,332 | 2011-12-13 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00327015 | A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Phase 3 | 1,306 | 2009-09-25 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT00683878 | Add-on to Thiazolidinedione (TZD) Failures | Phase 3 | 972 | 2017-02-23 | pioglitazone | Its name | ClinicalTrials.gov |
| NCT01183013 | 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks | Phase 3 | 936 | 2014-04-21 | pioglitazone | Its name | ClinicalTrials.gov |
1 to 10 of 449
See all 449 trialsComparisons in its trials127
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pioglitazone vs Placebo: Acute Coronary Syndrome | 206 of 1,939 | 249 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure | 206 of 1,939 | 249 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: Fatal or Non-fatal Stroke Alone | 127 of 1,939 | 154 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: All Cause Mortality | 136 of 1,939 | 146 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: Development of Overt Diabetes | 73 of 1,939 | 149 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction | 175 of 1,939 | 228 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Pioglitazone vs Placebo: serious adverse events | 950 of 1,939 | 987 of 1,937 | 3,876 | NCT00091949 | Trial comparisons |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Vital Signs | 0 of 1,532 | 0 of 589 | 2,121 | NCT00736099 | Trial comparisons |
| Old Lina vs New Lina: Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events | 82 of 1,532 | 37 of 589 | 2,121 | NCT00736099 | Trial comparisons |
| Old Lina vs New Lina: Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events | 209 of 1,532 | 86 of 589 | 2,121 | NCT00736099 | Trial comparisons |
1 to 10 of 127
See all 127 comparisons in its trialsPapers from its trials323
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials13
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test B | 4 | 2 | ConductCognition |
| Verbal Fluency | 4 | 1 | ConductCognition |
| Verbal Learning | 3 | 2 | ConductCognition |
| Category Fluency | 2 | 1 | ConductCognition |
| Clock Drawing Task | 2 | 1 | ConductCognition |
| Digit Span Test | 2 | 1 | ConductCognition |
| Picture Naming Test | 2 | 1 | ConductCognition |
| Symbol Coding | 2 | 1 | ConductCognition |
| Trail Making Test A | 2 | 2 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
1 to 10 of 13
See all 13 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL595
GET https://conductscience.org/api/drugs/v1/CHEMBL595/diseases?page=2